MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

The side effects of Ozempic (semaglutide) can include abdominal (belly) pain, diarrhea, nausea, and vomiting, among other digestive-related problems. Ozempic is not a high-risk medication for most ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Ozempic is a brand-name medication containing the active ingredient semaglutide. It belongs to the class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 agonists). It mimics the ...

Mar. 20, 2025 — Engineers have developed an approach for recycling cement waste into a sustainable, low-carbon alternative that is comparable in performance to the industry ... Producing Nuclear ...

The ISIS Neutron and Muon Source has presented three early-career researchers with its first ISIS Springboard Awards including Jennifer Johnstone-Hack from the School of Chemical, Materials and ...

[3.2 Lithium Battery News] Three Departments Announce Further Promotion of New Energy City Buses and Power Battery Equipment Upgrades ...